Zanubrutinib combination for newly diagnosed mantle cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of targeted drugs (zanubrutinib plus other medicines) in people newly diagnosed with mantle cell lymphoma. It aims to see how effective and safe these drugs are for different age groups, possibly helping control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with mantle cell lymphoma, a type of blood cancer.
- You should not have had any previous treatment for this lymphoma.
- You need to be at least 18 years old (for the younger group) or 65 years old and older (for the older group).
- You should be able to take care of yourself and be out of bed more than half the day.
- Your heart, liver, kidneys, and blood counts need to be in reasonably good shape.
- You must not have a history of blood clots in the past 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (bendamustine and rituximab) for people newly diagnosed with mantle cell lymphoma. It is designed for older adults, those with certain genetic changes (TP53), or those who cannot tolerate standard chemotherapy.
This study tests a combination of a targeted pill (zanubrutinib) with standard chemotherapy (R-CHOP/R-DHAP) for people newly diagnosed with mantle cell lymphoma. The goal is to see how well this approach works and to potentially improve treatment outcomes for this type of lymphoma.
This trial tests a new combination of three targeted therapies for people newly diagnosed with a high-risk form of mantle cell lymphoma (MCL), a rare blood cancer. The goal is to see if this combination is safe and effective in shrinking or eliminating the cancer.
This trial tests a combination of three drugs—obinutuzumab, zanubrutinib, and lenalidomide—as a first treatment for mantle cell lymphoma. The goal is to see if this approach is safe and effective for patients who have not had prior therapy.
This trial is testing a medicine called zanubrutinib to see if it can help prevent mantle cell lymphoma from coming back after initial treatment. It is for people who have already finished their first treatment and achieved at least a partial response.
This trial tests two targeted drugs, zanubrutinib and tafasitamab, for people with mantle cell lymphoma. The goal is to see if this combination works better than standard treatments.
Hear when a new Lymphoma, Mantle-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.